STAT+: Pharmalittle: Vertex exec says prices for gene therapies are ‘in the ballpark’; insulin access in poor countries remains spotty
STAT
OCTOBER 6, 2022
And yes, this is made available by the same folks who operate the distillery. Even a drug-price watchdog, the Institute for Clinical and Economic Review, deemed the $2.8 million tag as cost effective for a Bluebird Bio drug called Zynteglo for the blood disorder beta thalassemia, Arbuckle said in an interview.
Let's personalize your content